Meeting
2018 Gastrointestinal Cancers Symposium
Molecular and clinical characterization of BRAF mutations in pancreatic ductal adenocarcinomas (PDACs).
Authors
Michelle Guan
Cedars-Sinai Medical Center, Los Angeles, CA
Michelle Guan , R Joseph Bender , Michael J. Pishvaian , David Charles Halverson , Richard Tuli , Samuel Jacob Klempner , Zev A. Wainberg , Aatur D. Singhi , Emanuel Petricoin III, Andrew Eugene Hendifar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 214)
DOI
10.1200/JCO.2018.36.4_suppl.214
Abstract #
214
Poster Bd #
A11
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Genomic profiling of KRAS wide-type pancreatic ductal adenocarcinomas identifies targetable genetic alterations.
First Author: Deng Wei
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA–based genomic landscape of KRAS wild-type pancreatic adenocarcinoma.
First Author: Brendon Fusco
Poster
2021 ASCO Annual Meeting
Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).
First Author: Lucy Xiaolu Ma
Poster
2023 ASCO Annual Meeting
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.
First Author: Bach Ardalan